Cargando…

BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study

Hereditary mutations in BRCA1/2 genes increase the risk of breast cancer by 60–80% and ovarian cancer by about 20–40% in female carriers. Detection of inherited mutations in asymptomatic carriers allows for the implementation of appropriate preventive measures. BRCA1/2 genotyping is also important f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kowalik, Artur, Siołek, Monika, Kopczyński, Janusz, Krawiec, Kamila, Kalisz, Joanna, Zięba, Sebastian, Kozak-Klonowska, Beata, Wypiórkiewicz, Elżbieta, Furmańczyk, Jowita, Nowak-Ozimek, Ewelina, Chłopek, Małgorzata, Macek, Paweł, Smok-Kalwat, Jolanta, Góźdź, Stanisław
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057642/ https://www.ncbi.nlm.nih.gov/pubmed/30040829 http://dx.doi.org/10.1371/journal.pone.0201086

Ejemplares similares

The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish population
por: Kowalik, Artur, et al.
Publicado: (2017)

Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach
por: Kedzierawski, Piotr, et al.
Publicado: (2021)

Next-Generation Sequencing-Based Analysis of Clinical and Pathological Features of PIK3CA-Mutated Breast Cancer
por: Smok-Kalwat, Jolanta, et al.
Publicado: (2023)

Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications
por: Kowalik, Artur, et al.
Publicado: (2017)

BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
por: Ławniczak, Małgorzata, et al.
Publicado: (2016)

Founder BRCA1 mutations in Nepalese population
por: Mehta, Anurag, et al.
Publicado: (2022)

A Two-Year Follow-Up Cohort Study—Improved Clinical Control over CVD Risk Factors through Weight Loss in Middle-Aged and Older Adults
por: Macek, Pawel, et al.
Publicado: (2020)

Optimal cut-off values for anthropometric measures of obesity in screening for cardiometabolic disorders in adults
por: Macek, Pawel, et al.
Publicado: (2020)

Assessment of Age-Induced Changes in Body Fat Percentage and BMI Aided by Bayesian Modelling: A Cross-Sectional Cohort Study in Middle-Aged and Older Adults
por: Macek, Pawel, et al.
Publicado: (2020)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

Identification of a founder BRCA2 mutation in Sardinia
por: Pisano, M, et al.
Publicado: (2000)

Evidence of a founder BRCA1 mutation in Scotland
por: Liede, A, et al.
Publicado: (2000)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
por: Maksimenko, J., et al.
Publicado: (2018)

WHO recommendations on physical activity versus compliance rate within a specific urban population as assessed through IPAQ survey: a cross-sectional cohort study
por: Macek, Pawel, et al.
Publicado: (2019)

Age-Dependent Disparities in the Prevalence of Single and Clustering Cardiovascular Risk Factors: A Cross-Sectional Cohort Study in Middle-Aged and Older Adults
por: Macek, Pawel, et al.
Publicado: (2020)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

A Founder Mutation of the BRCA1-Gene in Western Sweden
por: Einbeigi, Zakaria, et al.
Publicado: (1999)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
por: Kluz, Tomasz, et al.
Publicado: (2018)

BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina
por: Solano, Angela R., et al.
Publicado: (2018)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients
por: Walczyk, Agnieszka, et al.
Publicado: (2020)

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls
por: Behl, Supriya, et al.
Publicado: (2020)

Competing Risks of Cancer and Non-Cancer Mortality When Accompanied by Lifestyle-Related Factors—A Prospective Cohort Study in Middle-Aged and Older Adults
por: Macek, Pawel, et al.
Publicado: (2020)

Characterization of an Italian Founder Mutation in the RING-Finger Domain of BRCA1
por: Caleca, Laura, et al.
Publicado: (2014)

The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population
por: Luo, Yu, et al.
Publicado: (2022)

Germline Mutations in BRCA1 and BRCA2 in Polish Families Predisposed to Breast and Ovary Cancers
por: Grzybowska, E., et al.
Publicado: (1999)

BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile
por: Alvarez, Carolina, et al.
Publicado: (2017)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

Exploring the Significance of Immune Checkpoints and EBV Reactivation in Antibody Deficiencies with Near-Normal Immunoglobulin Levels or Hyperimmunoglobulinemia
por: Mertowska, Paulina, et al.
Publicado: (2023)

Mutation Analysis of the BRCA1 and BRCA2 Genes in the Belgian Patient Population and Identification of a Belgian Founder Mutation BRCA1 IVS5+3A>G
por: Claes, Kathleen, et al.
Publicado: (1999)

The Icelandic founder mutation BRCA2 999del5: analysis of expression
por: Mikaelsdottir, Evgenia K, et al.
Publicado: (2004)

Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank
por: Abul-Husn, Noura S., et al.
Publicado: (2019)

Coexisting Germline CHEK2 and Somatic BRAF(V600E) Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course
por: Gąsior-Perczak, Danuta, et al.
Publicado: (2019)

BRCA1 4153delA founder mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2006)

Prevalence of the most frequent BRCA1 mutations in Polish population
por: Brozek, Izabela, et al.
Publicado: (2011)

BRCA1 and BRCA2 screening of nine Chilean founder mutations through allelic-discrimination and real-time PCR in breast/ovarian cancer patients
por: Alvarez, Carolina, et al.
Publicado: (2022)

New, fast and cheap prediction tests for BRCA1 gene mutations identification in clinical samples
por: Gajda-Walczak, Aleksandra, et al.
Publicado: (2023)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

BRCA Genetic Screening in Middle Eastern and North African: Mutational Spectrum and Founder BRCA1 Mutation (c.798_799delTT) in North African
por: Laraqui, Abdelilah, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j6dipadhsbmt1cp7v42foog4nr